Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size
Authors:
- Maria Reyes Jimenez-LeonMJMaria Reyes Jimenez-Leon
- Carmen Gasca-CapoteCGCarmen Gasca-Capote
- Cristina Roca-OportoCRCristina Roca-Oporto
- Nuria EspinosaNENuria Espinosa
- Salvador SobrinoSSSalvador Sobrino
- Maria Fontillon-AlberdiMFMaria Fontillon-Alberdi
- Ce GaoCGCe Gao
- Isabelle RosetoIRIsabelle Roseto
- Gregory GladkovGGGregory Gladkov
- Inmaculada Rivas-JeremiasIRInmaculada Rivas-Jeremias
- Karin NeukamKNKarin Neukam
- Jose German Sanchez-HernandezJSJose German Sanchez-Hernandez
Open Access
- 9 July 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (16)
Abstract
BACKGROUND: We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS: Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS: Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 + T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION: Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION: ClinicalTrials.gov NCT03577782. FUNDING: This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, “a way to make Europe,” research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/01532)
This publication has 73 references indexed in Scilit:
- Quantitative high‐throughput determination of endogenous retinoids in human plasma using triple‐stage liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2007
- Retinoic Acid Imprints Gut-Homing Specificity on T CellsImmunity, 2004
- Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA levelAIDS, 2004
- Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cellsNature Medicine, 2003
- Detecting hypermutations in viral sequences with an emphasis on G → A hypermutationBioinformatics, 2000
- Rebound of plasma HIV viral load following prolonged suppression with combination therapyAIDS, 1998
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences, 1997
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyScience, 1997
- The anatomical basis of intestinal immunityImmunological Reviews, 1997
- Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.The Journal of Immunology, 1994